Combretastatin A1 phosphate - Oncotelic Therapeutics
Alternative Names: CA1; CA1P; Combrestatin A1 diphosphate; Combretastatin A1 di-phosphate; OXi 4503Latest Information Update: 17 May 2022
At a glance
- Originator Arizona State University
- Developer Mateon Therapeutics; Oncotelic Therapeutics
- Class Antineoplastics; Combretastatins; Diphosphates; Stilbenes
- Mechanism of Action Tubulin polymerisation inhibitors; Vascular disrupting agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Acute myeloid leukaemia
Highest Development Phases
- Phase I/II Acute myeloid leukaemia; Liver cancer; Liver metastases; Myelodysplastic syndromes
- No development reported Solid tumours
Most Recent Events
- 11 May 2022 Oncotelic Therapeutics has patent protection for Oxi4503 in USA
- 20 Apr 2022 Oncotelic Therapeutics has patent protection for combretastatin A1 phosphate in the US
- 15 Apr 2021 Phase I/II development for Acute myeloid leukaemia and Myelodysplastic syndromes is still underway in USA (Mateon Therapeutics pipeline, April 2021)